Skip to main content
. Author manuscript; available in PMC: 2009 Apr 8.
Published in final edited form as: Br J Haematol. 2008 Dec 10;144(4):603–612. doi: 10.1111/j.1365-2141.2008.07509.x

Table I.

Expansion of SRC by recombinant hoxb4

Experiment Treatment Positive/Total % Positive SRC frequency
I Control 9/15 60 1 in10989
I T-hoxb4-H 13/17 76 1 in 6910
II Control 4/15 26 1 in 16118
II T-hoxb4-H 7/14 50 1 in 7213
III Control 4/15 26 1 in 16118
III T-hoxb4-H 8/14 57 1 in 5901

Human cord blood CD34+ cells were cultured for four days in the StemSpam media with 50nM BSA control or T-hoxb4-H. Cells were harvested, washed and injected into sub-lethally-irradiated (2.5Gy) NOD/SCID mice, each mouse received cells equivalent to 104 (experiment I) or 5 × 103 (experiment II and III) starting CD34+ cells. Animals were euthanized eight weeks later; the presence of human CD45+ cells in the recipient BM cells was analyzed by flow cytometry. Mice with 0.1% or high human CD45+ cell in the BM were recorded as positive of human HSC engraftment. SRC frequency was calculated by using the Poission equation Pi=e(-N) × (Ni/i!) to calculate P0. Data shown were from three independent experiments.